Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Kenneth F. Grossmann"'
Autor:
Islam Eljilany, Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J. Lee, Megan Othus, James Moon, John M. Kirkwood, Vernon K. Sondak, Antoni Ribas, Kenneth F. Grossmann, Ahmad A. Tarhini
Publikováno v:
Cancers, Vol 15, Iss 9, p 2561 (2023)
Background: Treatment with immune checkpoint inhibitors (ICIs) has been linked to granulomatous and sarcoid-like lesions (GSLs) affecting different organs. This study sought to evaluate GSL incidence in patients with high-risk melanoma treated with c
Externí odkaz:
https://doaj.org/article/0c952d5ea56f4c0db38c40788397d83f
Autor:
Justin C. Moser, Danli Chen, Siwen Hu‐Lieskovan, Kenneth F. Grossmann, Shiven Patel, Sarah V. Colonna, Jian Ying, John R. Hyngstrom
Publikováno v:
Cancer Medicine, Vol 8, Iss 18, Pp 7637-7643 (2019)
Abstract Background The optimal treatment sequence for patients with advanced BRAF V600 mutant melanoma is unknown. BRAF/MEK inhibition (BRAF/MEKi), single agent anti‐PD‐1 (aPD‐1) antibodies and combination immune checkpoint inhibition with niv
Externí odkaz:
https://doaj.org/article/52b6fa49a3e44388aa94c0a04848fd13
Autor:
Susan R. Pfeffer, Kenneth F. Grossmann, Pamela B. Cassidy, Chuan He Yang, Meiyun Fan, Levy Kopelovich, Sancy A. Leachman, Lawrence M. Pfeffer
Publikováno v:
Journal of Clinical Medicine, Vol 4, Iss 12, Pp 2012-2027 (2015)
MicroRNAs (miRNAs) are a class of 22–25 nucleotide RNAs that control gene expression at the post-transcriptional level. MiRNAs have potential as cancer biomarkers. Melanoma is a highly aggressive form of skin cancer accounting for almost 4% of canc
Externí odkaz:
https://doaj.org/article/79606a2ba639478a9d2865552a02e8f6
Autor:
Kenneth F. Grossmann, Kim Margolin
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 7 (2015)
Historically, stage III–IV melanoma patients have had few options to achieve long-term survival. For patients with stage III disease, surgery alone may be curative for approximately 50%. Adjuvant treatment with a slightly greater impact on relapse-
Externí odkaz:
https://doaj.org/article/ed2efe9fb163479e997b7917e7a66bc7
Autor:
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Publikováno v:
New England Journal of Medicine. 388:813-823
Autor:
Antoni Ribas, John M. Kirkwood, Larissa A. Korde, Elad Sharon, Nageatte Ibrahim, Sama Ahsan, Scot W. Ebbinghaus, Krishna S. Gunturu, Magdalena Kovacsovics-Bankowski, Brian Gastman, Zeynep Eroglu, James Moon, Hongli Li, Douglas B. Johnson, Ragini R. Kudchadkar, Bartosz Chmielowski, Robert M. Conry, Karl D. Lewis, Pauline Funchain, Kari Kendra, Elizabeth I. Buchbinder, Justine V. Cohen, Nikhil I. Khushalani, Thach-Giao Truong, Teresa M. Petrella, Michael V. Knopp, Vernon K. Sondak, Ahmad A. Tarhini, Sapna P. Patel, Megan Othus, Kenneth F. Grossmann
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70860ad8a591df39f1504fb8bc1ae75a
https://doi.org/10.1158/2159-8290.22541236.v1
https://doi.org/10.1158/2159-8290.22541236.v1
Autor:
David F. McDermott, Avivit Peer, Neeraj Agarwal, Michael B. Atkins, Jerry Cornell, Rodolfo F. Perini, Kenneth F. Grossmann, Howard Gurney
Publikováno v:
Cancer Research. 83:CT120-CT120
Background: First-line treatment with immunotherapy alone or in combination with antiangiogenic agents is a standard of care for advanced RCC. Many patients (pts) develop resistance to first-line treatment and effective second-line and beyond options
Autor:
Siwen Hu-Lieskovan, James Moon, John Hyngstrom, Katie M. Campbell, Gino K. In, Theodore F. Logan, Kari L. Kendra, Ding M. Wang, Douglas B. Johnson, Gary C. Doolittle, Alan Tan, Ann W. Silk, Kenneth F. Grossmann, Christopher W. Ryan, Sapna P. Patel, Shay Bellasea, Michael C. Wu, John M. Kirkwood, Helen X. Chen, Antoni Ribas
Publikováno v:
Cancer Research. 83:3275-3275
We hypothesize that a significant number of patients do not respond to PD-1/L1 blockade because there are no pre-existing tumor antigen-specific T-cells, and this can be addressed by combination therapy with an oncolytic virus such as T-VEC. S1607 is
Autor:
David F. McDermott, Avivit Peer, Neeraj Agarwal, Michael B. Atkins, Jerry Cornell, Rodolfo F. Perini, Kenneth F. Grossmann, Howard Gurney
Publikováno v:
Journal of Clinical Oncology. 41:TPS747-TPS747
TPS747 Background: The combination of immunotherapy with antiangiogenic agents is a well-established first-line treatment option for patients (pts) with advanced renal cell carcinoma (RCC), but many pts develop resistance, and effective second- or su
Autor:
Brian R. Gastman, Martin D. Fleming, Anthony J. Olszanski, Jeffrey A. Sosman, Samantha Guild, April K.S. Salama, Susan M. Swetter, Dominick J. DiMaio, Douglas B. Johnson, Richard W. Joseph, Ryan M. Lanning, Rohit Sharma, Joseph J. Skitzki, Anjela Galan, Alison B. Durham, Anita M. Engh, Joel M. Baumgartner, Kenneth F. Grossmann, Genevieve M. Boland, Kari Kendra, Bartosz Chmielowski, Patrick A. Ott, Mark R. Albertini, Giorgos C. Karakousis, Kim Margolin, Nicole R. McMillian, Julie R. Lange, Merrick I. Ross, Christopher A. Barker, Evan Wuthrick, John A. Thompson, Ryan C. Fields, Ashley M. Holder
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:364-376
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), Sys